NCT00703807View on ClinicalTrials.gov

Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Endometrial Cancer
Interventions
DRUG

Topotecan

Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days

DRUG

RAD001

Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd

Trial Locations (1)

06520

Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Yale University

OTHER

NCT00703807 - Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers | Biotech Hunter | Biotech Hunter